ArticleBone marrow transplantation2006
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Article in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.The Cochrane database of systematic reviews · 2017Pooled it
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Trial
- Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.Oncotarget · 2018Review
- Article
- Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.Oncology letters · 2015Article
- Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project.Drug safety · 2015Review
- Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.Core evidence · 2015Review
- Tumor lysis syndrome: new challenges and recent advances.Advances in chronic kidney disease · 2014Review
- Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.British journal of clinical pharmacology · 2013Article
- One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.Ecancermedicalscience · 2013Article
- Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies.Journal of hematology & oncology · 2012Review
- Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.Bone marrow transplantation · 2011Article
- Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.Journal of blood medicine · 2011Article
- Rasburicase improves hyperuricemia in infants with acute kidney injury.Pediatric nephrology (Berlin, Germany) · 2010Article
- Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).Biologics : targets & therapy · 2008Article
- Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.International journal of medical sciences · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant urate oxidase (rasburicase) lowers uric acid levels rapidly to very low levels at the labeled dose of 0.15-0.2 mg/kg daily for 5 days. Our past experience showed that a lower dose (3 mg) lowered uric acid levels sufficiently in most patients. A retrospective review was conducted to determine the effect of a fixed 3 mg dose of rasburicase in 43 adult patients with cancer undergoing hematopoietic stem cell transplantation or receiving chemotherapy who had elevated or rising uric acid levels (6.4-16.8 mg/dl; median 9.6). Six patients received a second dose of rasburicase (3 mg in four patients and 1.5 mg in two patients) 24 h later. Patients received allopurinol, adequate hydration, as well as other supportive therapy as required. Uric acid levels declined by 6-95% (median 43%) within the first 24 h after rasburicase administration, and levels at 48 h were 9-91% (median 65%) lower than the baseline levels. Serum creatinine changed by < or =10% in 21 patients, increased by >10% in four patients and decreased by >10% in 18 patients. No significant renal dysfunction developed in any of the patients. We conclude that rasburicase is effective in lowering uric acid levels at a fixed dose of 3 mg, which is much lower than the recommended dose.
Indexed as
Identifiers
16708061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.